Abstract An understanding of the role of inherited cancer predisposition syndromes in pediatric tumor diagnoses continues to develop as more information is learned through the application of genomic technology. Identifying patients and their relatives at an increased risk for developing cancer is an important step in the care of this patient population. The purpose of this review is to highlight various tumor types that arise in the pediatric population and the cancer predisposition syndromes associated with those tumors. The review serves as a guide for recognizing genes and conditions to consider when a pediatric cancer referral presents to the genetics clinic.
Introduction
Childhood cancers comprise less than 1% of all new cancer diagnoses each year, yet they are the second leading cause of death in children after accidents. Though most studies have focused on adult cancer populations, one study of a pediatric cancer survivorship clinic reported that based on family history, tumor type or physical findings, greater than 25% of patients seen should be considered for referral to a cancer genetics clinic (Knapke et al. 2012 ). If such patients are missed, individuals at-risk for a pediatric cancer predisposition syndrome may not be evaluated in time for early detection and prevention of future cancers in themselves or their relatives. More recent studies looking at the utility of genomic scale sequencing in the pediatric cancer population have reported identification of both long-standing tumor-type/genotype associations as well as previously unrecognized associations suggesting that a broader evaluation of this patient population may be appropriate (Parsons et al. 2016; Zhang et al. 2015a) .
The purpose of this review is to highlight various tumor types that can arise in the pediatric population and their associated cancer predisposition syndromes. Considerations such as pathology, age of onset and other clinical features of the tumor are addressed when appropriate. Somatic gene mutations and translocations are not addressed. Because in-depth information about each syndrome and its associated features is beyond the scope of this paper, summaries of each can be found in Table 1 , including the most common physical features, dermatologic findings and other common tumors associated with each syndrome. In addition, the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors have published practice guidelines providing detailed referral indications for cancer predisposition assessment for common syndromes, some of which include pediatric onset. Conditions included within the practice guidelines are marked with an asterisk in Table 1 for reference (Hampel et al. 2015) . Table 2 serves as a quick reference guide for the tumor types and associated syndromes as presented within the review. The associations reported throughout this review range from strong to rare. Not all tumor types may warrant a referral or genetic testing in the absence of other clinical features or relevant personal or family history. Some tumor types may not prompt referral when diagnosed in an adult, but when diagnosed in childhood, referral may be indicated. The ideal threshold for referral, however, is currently unclear and practices are inconsistent. Consensus in the field is needed to develop guidance on referral recommendations.
Although not the focus of this review, unique concerns present when considering genetic testing within a pediatric oncology setting. Plon and Malkin highlight issues for consideration when pursuing genetic testing including: the genetic heterogeneity of pediatric cancer susceptibility, the technical aspects of genetic testing and interpreting test results, and psychosocial aspects of genetic testing within this population (Plon and Malkin 2016) . Additional counseling considerations include the appropriate timing of offering testing, genetic testing in minors, management decisions and the availability of recommended surveillance guidelines (Schneider and Jasperson 2015) . It is important to recognize that comprehensive genetic counseling should occur for any patient/ family being offered genetic testing. Furthermore, a multidisciplinary approach involving varied clinical expertise can prove fruitful and will maximize patient care.
Central Nervous System (CNS) Tumors Choroid Plexus Carcinoma (CPC)
CPCs arise in the choroid plexus of the lateral ventricles of the brain. They account for 1-4% of all pediatric intracranial brain tumors (Grygotis and Chew 1997) . Presentation of CPCs may occur at any age, even prenatally (Vassallo et al. 2012; Wilhelm et al. 2012) , but the mean age of diagnosis is usually before 3.5 years (Boyd and Steinbok 1987; Pencalet et al. 1998; Wolff et al. 2002; Wrede et al. 2007 ). They are frequently seen in association with Li-Fraumeni syndrome (LFS) (Gozali et al. 2012; Krutilkova et al. 2005) . In a study by Gozali et al., results revealed that among individuals with a CPC and a personal and/or family history suggestive of LFS, 36.4% were positive for a mutation in the TP53 gene (Gozali et al. 2012) . While the majority of individuals with LFS have a family history of multiple cancers at a young age (85-90%), de novo mutations (10-15%) do occur (Gozali et al. 2012; Wang and Cornford 2002) . Individuals with CPC meet National Comprehensive Cancer Network guidelines for germline TP53 testing regardless of family history, according to revised Chompret criteria ((NCCN) 2017).
Cortical Tuber
Cortical tubers are found in the outer layer of the brain (cortex). They are common to tuberous sclerosis complex (TSC) and affect greater than 80% of individuals with TSC (Crino et al. 2006) . These lesions can present as early as in utero but usually present in early childhood (Park et al. 1997) . The number of cortical tubers has independently been found to be associated with worse cerebral dysfunction including greater seizure activity, developmental delay and intellectual disability (Goodman et al. 1997) . Individuals who have mutations in the gene, TSC2, have a more severe disease presentation compared to those with a mutation in TSC1 (Dabora et al. 2001) .
Ependymoma
Ependymomas arise from ependymal cells, which line the ventricles of the brain and the central region of the spinal cord. Most intraventricular lesions develop in the floor of the fourth ventricle among children (58%). Ependymomas account for 10% of all pediatric brain tumors and about a third develop before three years of age . Ependymomas are the second most common type of pediatric spinal cord tumor (Yuh et al. 2009 ). Most are solitary lesions (Parsa et al. 2005) ; however, multiple synchronous primary spinal cord ependymomas are seen in association with neurofibromatosis type 2 (NF2) (Bydon et al. 2013; Plotkin et al. 2011) . The true incidence of ependymomas among individuals with NF2 is not clear. Two small studies evaluating spinal cord tumors in NF2 report an incidence of spinal cord ependymomas of 1.5-6.2% (Mautner et al. 1996; Parry et al. 1994) . The average age at presentation among these individuals was 28.7 years with an age range of 12-44 years.
Ependymomas are also among the brain tumors seen in association with familial adenomatous polyposis (FAP), which results from a mutation in the APC gene. Among the 1% of individuals with FAP who develop brain tumors, 10% are ependymomas with an average age of onset of approximately 16.3 years (Attard et al. 2007) . Ependymomas may present as multiple lesions in individuals with FAP (Mullins et al. 1998; Torres et al. 1998 ).
Embryonal CNS Tumors
Atypical Teratoid/Rhabdoid Tumor (AT/RT) RTs can be found in soft tissue or in the brain. When present in the brain they are referred to as atypical teratoid/rhabdoid tumors (AT/RT) and are highly malignant, aggressive tumors. They account for 1-6% of all pediatric brain tumors (Kaderali et al. 2009; Woehrer et al. 2010) . They are most often diagnosed by the loss of the SMARCB1, or INI1, protein on immunohistochemistry staining (Bourdeaut et al. 2007 ). The formation of RTs can be due to a germline mutation in the SMARCB1/INI1 gene, termed rhabdoid tumor predisposition syndrome type 1 (RTPS1). The most comprehensive study demonstrated a 38.5% germline mutation rate in SMARCB1/ INI1 in children with AT/RTs, and approximately 35% rate in children with any RT (Eaton et al. 2011) . Of the 35% that have a germline SMARCB1/INI1 mutation, about 32% inherited the mutation from a parent, none of which had a history of RT. These numbers demonstrate both the high de novo mutation rate and evidence of incomplete penetrance. This study also reported a 9% gonadal mosaicism rate with more than one child testing positive for a mutation and parents testing negative on peripheral blood. Typically, individuals with RT caused by a germline SMARCB1/INI1 mutation will develop the tumor in the first year of life. Previously, reports indicated that individuals with germline predisposition will have a worse prognosis than individuals with a non-SMARCB1/INI1 germline related tumor (Savla et al. 2000) , however, more recent reports indicate that this may not be the case (Kordes et al. 2014) . It is believed that there are other genes within this complex that predispose to develop RTs since there are familial RT families that retain SMARCB1 protein on IHC staining (Bourdeaut et al. 2007; Eaton et al. 2011; Fruhwald et al. 2006) . Recently SMARCA4 has also been identified as a gene associated with a predisposition to the development of RTs, referred to as rhabdoid tumor predisposition syndrome type 2 (RTPS2). A small study on AT/RTs suggests that loss of SMARCA4 staining in AT/RT tumors is associated with a high SMARCA4 germline mutation rate .
Ciliary Body Medulloepithelioma (CBME) CBME is a rare intraocular neoplasm. The true incidence of this lesion is not clear. CBMEs have been reported infrequently in association with DICER1 syndrome, which arises due to a mutation in the DICER1 gene (Hill et al. 2009 ). Among the cases reported, diagnosis was prior to 16 years of age (de Kock et al. 2014b; Priest et al. 2011; Ramasubramanian et al. 2013 ).
Medulloblastoma (MB)
MBs develop in the cerebellum and are the second most common brain tumor among children and teens accounting for 10% of pediatric brain tumors (Kaderali et al. 2009 ). In a series of patients less than 14 years of age with MB, 6% had nevoid basal cell carcinoma syndrome (NBCCS)/Gorlin syndrome (Gorlin 2004) , due to a mutation in the PTCH1 gene. One study reported up to a 5% incidence of MBs in individuals with NBCCS (Gorlin 2004) . The average age of onset of MB in this population is 1-2 years compared to 7-8 years in the general population (Garre et al. 2009; Gorlin 2004) . The subtype of MBs seen in association with NBCCS is predominantly MB with extensive nodularity (MBEN) and the cerebellar vermis is the most common location (Garre et al. 2009 ). Mutations in the PTCH2 gene have also been seen infrequently in association with individuals harboring features of NBCCS (Fujii et al. 2013) including MBs (Smyth et al. 1999) .
Mutations in SUFU, a tumor suppressor gene that is part of the SHH pathway, predispose to MBs, primarily the desmoplastic MB and MB with excessive nodularity subtypes. Affected families display incomplete penetrance and most reported cases have occurred before four years of age (Brugieres et al. 2010; Brugieres et al. 2012; Taylor et al. 2002) . More recent research has identified SUFU mutations in a subset of individuals with clinically diagnosed NBCCS who have tested negative for PTCH1 mutations. Initial studies suggest that the risk of MB is higher in those patients harboring SUFU versus PTCH1 mutations .
Amongst the individuals with FAP who develop brain tumors, 60% are MB. The age of onset among cases in the literature ranges from 5 years to well into adulthood. Some have presented prior to the onset of polyposis, with most presenting between 13.5 and 18.5 years (Attard et al. 2007; Paraf et al. 1997) . There is some evidence of genotype-phenotype correlations among APC mutation carriers. The greatest risk for MBs (13 fold) is among individuals with mutations in codons 679-1224 (Attard et al. 2007 ).
There are a number of studies in the medical literature describing the association between LFS and MBs. Among the reported cases, the average age of onset is about 4.2 years (Malkin et al. 1990; Pearson et al. 1982; Rieber et al. 2009; Yamazaki et al. 2000) . Recent studies have described the benefit of tumor expression profiling for MB prognostication. MBs can be subdivided into four groups including WNT, SHH, group 3 and group 4. SHH/TP53 MBs have the most dismal outcome. Zhukova et al. describe a subgroup of SHH/ TP53 MBs with germline TP53 mutations in their cohort and recommend genetic counseling for all individuals diagnosed with a SHH/TP53 MB profile (Zhukova et al. 2013) .
Fanconi anemia (FA) includes multiple different subtypes. Individuals with the subtype FANCD1 are at an increased risk for MB at an early age (~3.8 years) Hirsch et al. 2004; Offit et al. 2003) . FANCD1 results from biallelic inheritance of BRCA2 mutations. Among a study by Alter et al., of 27 individuals with FANCD1, 30% developed MB ). Individuals with FA may present with a MB prior to the other features of the condition and may not have physical features characteristic for FA, making it difficult to make the diagnosis (Hirsch et al. 2004) . A second subtype, FANCN, results from biallelic inheritance of mutations in the PALB2 gene. Individuals with FANCN are at risk for MBs with an average age of onset of 2.5 years. In a small study of individuals with this rare subgroup of FANCN (n = 7), 71% had MB (Reid et al. 2007) . Chromosome breakage studies can be performed as a diagnostic study in cases where a diagnosis of FA is in question.
MBs have been reported in 11.6% of the brain tumors associated with constitutional mismatch repair deficiency syndrome (CMMRD), a condition that arises due to biallelic inheritance of mutations in one of four mismatch repair genes (MLH1, MSH2, MSH6, and PMS2). The average age of onset of MB among individuals with CMMRD is about 7 years (Wimmer et al. 2014) .
Occurrences of MB have also been reported infrequently in association with the autosomal recessive conditions ataxia telangiectasia (AT) (Roelfsema and Peters 2007) , RubinsteinTaybi syndrome (Evans et al. 1993; Miller and Rubinstein 1995; Roelfsema and Peters 2007) , and Nijmegen breakage syndrome (NBS) (Distel et al. 2003) . Rare cases of MB have more recently been reported in children carrying heterozygous mutations in the NBN gene (Ciara et al. 2010) , the association of which will need to be further explored.
Pituitary Blastoma (PB)
PBs are rare tumors arising in the pituitary gland. The incidence of these neoplasms is not clear at this time. They can be seen in association with DICER1 syndrome. Of the limited case reports in the medical literature, the average age of onset is 11.4 months with an age range of 7-24 months (de Kock et al. 2014a; Sahakitrungruang et al. 2014) .
Primitive Neuroectodermal Tumor (PNET)
PNETs arise from neural crest cells/neuroectoderm. They account for approximately 4% of pediatric CNS tumors (Kaderali et al. 2009 ) and are seen in about 10% of CMMRD-related brain tumors with a median age at diagnosis of 8 years (range 4-17 years) (Wimmer et al. 2014) . PNETs have also been reported in association with LFS (Schniederjan et al. 2009; Stecher et al. 2008 ) but at a frequency that appears to be less than CPCs. Among the limited case reports in the medical literature, the age of onset ranges from 10 to 14 years. FANCD1 is infrequently reported in association with PNETs (Dewire et al. 2009 ).
Gangliocytoma
A cerebellar dysplastic gangliocytoma is a slow growing, benign hamartomatous lesion that is commonly referred to as Lhermitte-Duclos disease (LDD). It is pathognomonic for PTEN hamartoma tumor syndrome (PHTS), also known as Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome, due to a mutation in the PTEN gene (Nelen et al. 1996) . The average age of onset of LDD is between 20 and 30 years; however, these lesions can develop in childhood (Duchowny et al. 1989; Pilarski 2009; Wells et al. 1994) . Children with LDD may not have developed the other manifestations of PHTS at the time of diagnosis as this condition is infrequently diagnosed before 18 years (Lachlan et al. 2007 ). The frequency of LDD among individuals with PHTS is not clear (Pilarski 2009; Tan et al. 2007) , however, in a small study by Lok et al., 15% had LDD (Lok et al. 2005) .
Gliomas
Anaplastic Astrocytoma (AA)
AAs are grade III tumors that account for approximately 5% of pediatric CNS tumors (Kaderali et al. 2009 ). These tumors can be seen in association with CMMRD. Among the cases reported in the medical literature, the average age of onset is 10 years (Durno et al. 2012; Ilencikova et al. 2011; Ostergaard et al. 2005; Toledano et al. 2009; Wimmer and Etzler 2008; Wimmer and Kratz 2010) .
AAs can infrequently be seen among the array of extracolonic tumors seen in FAP (Attard et al. 2007 ). However, the frequency with which they occur among children with FAP and average ages of onset are not clear.
AAs have been reported in individuals with melanoma neural system tumor syndrome, a rare condition due to a contiguous gene deletion on 9p21 encompassing the p16/ CDKN2A, p14/CDKN2B and p15/CDKN2B gene cluster. Exon 1 and the promoter of ANRIL have also been deleted in at least two very large families with this condition. Astrocytic tumors in these families have been reported in children, teens and adults (Bahuau et al. 1998; Bahuau et al. 1997; Kaufman et al. 1993; Pasmant et al. 2007; Randerson-Moor et al. 2001 ).
Glioblastoma Multiform (GBM)
GBMs are high grade tumors that develop in the cerebral hemispheres of the brain. They account for about 2-3% of all pediatric brain and CNS tumors (Dolecek et al. 2012; Kaderali et al. 2009 ). They can arise as primary brain tumors or transform from a lower grade glioma to a secondary GBM (Jaeckle et al. 2011) . Approximately 69-73% of the brain tumors seen in individuals with CMMRD are GBM with a mean age of onset of 9.5 years (Wimmer et al. 2014) . Those with biallelic mutations in MSH6 or PMS2 have been shown to have a higher rate (55%) of brain tumors, primarily GBM, when compared to individuals with biallelic mutations in MSH2 or MLH1 (Wimmer et al. 2014) . Individuals with heterozygous germline mutations in one of the MMR genes have Lynch syndrome and can have an increased risk of developing GBM, yet the frequency is not clear, nor is the frequency in which these develop in children vs. adults (Lusis et al. 2010; Paraf et al. 1997) . Wimmer et al. found that 50% of individuals with CMMRD who developed brain tumors harbored two PMS2 mutations, and most did not have a family history consistent with Lynch syndrome in a European cohort (Wimmer et al. 2014) .
Less frequently, individuals with FAP may develop a GBM (Lusis et al. 2010; Paraf et al. 1997 ). Paraf et al. describes several individuals with FAP who were diagnosed with a GBM between 13 and 80 years of age (Paraf et al. 1997) . There are also a number of case reports of GBM in association with LFS (Guha et al. 1995; Schiffman et al. 2008; Tachibana et al. 2000; Yamada et al. 2009 ).
Oligodendroglioma (ODG)
ODGs can be found in the cerebral hemispheres of the brain, but they primarily arise in the frontal and temporal regions, can be low or high grade (anaplastic ODG), or mixed (ODGastrocytomas) (Engelhard et al. 2002; Wagner et al. 2015) , and primarily affect adults. They account for~1-4% of primary pediatric brain tumors and 3-10% of all pediatric gliomas (Das et al. 2014; Kaderali et al. 2009; Rosemberg and Fujiwara 2005) . ODGs do not frequently arise due to germline mutations; however, pediatric case reports of ODGs have been reported among those with CMMRD (De Rosa et al. 2000; Menko et al. 2004; Poley et al. 2007 ) and at least one teen with Lynch syndrome (Heath et al. 2013) . Germline mutations in POT1 have also been newly identified among families with familial glioma, more specifically ODGs, mixed gliomas, and astrocytomas; however, the risk of developing these tumors among the pediatric population in not clear and requires further investigation (Bainbridge et al. 2015) .
Optic Pathway Glioma (OPG)
OPGs are low grade gliomas of the optic nerves that account for 3-5% of all pediatric CNS tumors (Fried et al. 2013) . Neurofibromatosis type 1 (NF1) is a genetic condition caused by a mutation in the NF1 gene that predisposes to a number of neoplasms including OPGs (Thiagalingam et al. 2004) . They are the most common intracranial malignancy in NF1 (Rosser and Packer 2002a) affecting 15-20% of individuals with the condition (Lewis et al. 1984; Listernick et al. 1994) . OPGs usually present before age 6 (Czyzyk et al. 2003; Listernick et al. 1994 ) but some research reports that they can develop into the teen years (Listernick et al. 2004 ). Czyzyk et al. (2003) reported an incidence of NF1-related OPGs vs. sporadic OPGs of 61.4% vs. 38.6%, among their cohort. Multifocal/bilateral presentation and tumors of the optic nerves are more commonly seen in individuals with NF1 whereas isolated chiasmal lesions are more common to sporadic OPGs (Chateil et al. 2001; Czyzyk et al. 2003; Kornreich et al. 2001) . Individuals with NF1-OPGs tend to have a less severe presentation and course compared to sporadic OPGs (Czyzyk et al. 2003; Kornreich et al. 2001) , and may spontaneously regress (Parsa et al. 2001 ).
Subependymal Giant Cell Astrocytoma (SEGA)
SEGAs arise in 10-20% of individuals with TSC (Roth et al. 2013) . SEGAs are almost always seen in association with TSC. There are case reports of isolated SEGAs, although it is possible that these tumors have somatic mutations in TSC1 or TSC2, or the individuals with these tumors may have somatic mosaicism for TSC (Jóźwiak et al. 2004 ). They have a mean age of diagnosis of 9.4 years and may enlarge over time causing significant morbidity (Goh et al. 2004; Torres et al. 1998 ).
Meningioma
Meningiomas arise in the arachnoid layer (covering) of the brain and spinal cord and are the most common primary CNS tumor in adults, but are typically considered benign. Fewer than 2% are considered malignant, and approximately one third are considered atypical (Smith 2015) . They account for about 1-3% of pediatric CNS tumors (Dolecek et al. 2012; Kaderali et al. 2009 ). Meningiomas may occur as treatment related secondary cancers in pediatric patients within the radiation field; however they can be a long-term complication of cancer therapy, which may not present before adulthood (Morgenstern et al. 2016) . The majority of meningiomas are sporadic and may be asymptomatic (Kuratsu et al. 2000) , as 1-2% are first identified on autopsy (Nakasu et al. 1987 ). Half of individuals with NF2 develop meningiomas (Goutagny and Kalamarides 2010) and it may be the presenting feature . The lifetime risk for developing meningioma among those with NF2 is approximately 80%. Onset has been reported to range in age from 2.5-80 years (Smith et al. 2011 ). Compared to sporadic tumors, meningiomas seen in NF2 tend to have a higher grade (II or III), may have a more aggressive morphology, have a greater chance of malignant progression, and progress more rapidly compared to sporadic meningiomas (Perry et al. 2001) .
Meningiomas are second to MBs with regard to frequency of CNS tumors seen in NBCCS (Gorlin 2004) . Approximately 2-4% of individuals with NBCCS have meningiomas (Endo et al. 2012; Rushing et al. 2005) . The average age of onset reported in a series of individuals with NBCCS and meningiomas was approximately 40.75 years (Kijima et al. 2012 ); however, meningiomas will infrequently present in childhood and the teen years (Kijima et al. 2012; Sobota et al. 2007 ). Meningiomas may also occur due to germline mutations in other genes, such as SUFU, SMARCB1, and SMARCE1, which specifically is associated with clear cell histology. The frequency with which they occur among mutation carriers for these genes and the ages of onset is not clear as there are a limited number of reported cases (Aavikko et al. 2012; Bacci et al. 2010; Smith et al. 2013; Smith et al. 2014; Smith et al. 2012 ).
Pineoblastoma (PB)
PBs are high grade tumors of the pineal gland that represent <1% of pediatric CNS tumors (Kaderali et al. 2009 ). Individuals with hereditary retinoblastoma (RB) are at increased risk to develop tumors outside of the retina including the pineal gland. When a PB presents with bilateral RB, it is referred to as trilateral disease (TRb). Individuals with TRb usually have an early age of onset of bilateral RB (mean 5 months) but it can present before ocular disease (Kivela 1999) . The average time of diagnosis of TRb after development of RB is approximately 21 months with the average age of diagnosis of TRb of 26 months (Kivela 1999) . For individuals with RB due to an RB1 de novo or familial germline mutation, the risk to develop TRb is 3-5% (de Jong et al. 2015) . The risk of trilateral disease among those with unilateral RB is estimated to be 0.5% (Kivela 1999) . DICER1 mutations have also been found infrequently in association with PBs in children as young as 2 years to 24 years of age (de Kock et al. 2014a; Sabbaghian et al. 2012 ).
Peripheral Nervous System Tumors Malignant Nerve Sheath Tumor (MNST)
MNSTs are aggressive soft tissue sarcomas of neuronal origin. They are most often seen in the extremities followed by the trunk, head, and neck, respectively. Approximately 50% of MNSTs are seen in individuals with NF1 (Farid et al. 2014 ). Although they are seen more often in adults (average age 29 years), a study in children with MNST showed a median age of diagnosis of 16.2 years among those with NF1 (deCou et al. 1995). Evans et al. report a risk of 8-13% for individuals with NF1 to develop a MNST (Evans et al. 2002) . In general, MNSTs appear at an earlier age and more aggressively in individuals with NF1 (Thway and Fisher 2013) than in those without a heritable syndrome. A subgroup of MNSTs, formerly called malignant triton tumors (MTTs), with rhabdomyoblastic differentiation is strongly associated with NF1. An analysis of 36 patients, both adults and children, with this subtype of MNST showed that 69% had NF1 (Brooks et al. 1985) . Infrequently, MNSTs have been reported in association with NF2, schwannomatosis, and LFS .
Neurofibroma
Neurofibromas are benign peripheral nerve tumors. They may be cutaneous (multiple and localized), plexiform, or intraneural and localized. Cutaneous neurofibromas tend to appear in the teenage years to young adulthood (Tonsgard 2006) . Whereas 90% are isolated lesions, 10% of cases are associated with NF1 (Rosser and Packer 2002b) . Plexiform neurofibromas occur in approximately 30% of individuals with NF1. They may be present at birth or develop during childhood ). Many plexiform neurofibromas may go undetected, therefore, the prevalence may be higher than reported (Tonsgard et al. 1998) . Intraneural neurofibromas are the form most likely to be a precursor to MNST (Thway and Fisher 2013) .
Although the numbers are small, neurofibromas have been described in individuals with CMMRD, increasing the phenotypic overlap between the two conditions (Wang et al. 1999; Wimmer et al. 2014) . Neurofibromas have been reported infrequently in persons with NF2 .
Schwannoma
Schwannomas are usually benign tumors that arise from Schwann cells in the insulating myelin sheath covering of peripheral nerves. They can be seen in tumor predisposition syndromes including NF2 and schwannomatosis . Peripheral schwannomas occur in approximately 70% of patients with NF2. Although schwannomas in NF2 have similar morphology to sporadic tumors they are more likely to have multifocal nerve involvement and Bwhorl formation^ (Ammoun et al. 2014) . Vestibular schwannomas (VS) are the most common tumor seen in individuals with NF2 (Lloyd and Evans 2013) . Approximately 50% of all NF2 cases are de novo (Evans et al. 1992) and it is estimated that 33% of de novo cases presenting with bilateral VS are mosaic. This number is estimated to be as high as 60% in unilateral cases (Evans et al. 2007 ). An individual under the age of 18 years presenting with an isolated VS is estimated to have a 10% risk of having NF2 (Evans et al. 2007) . Symptoms related to VS are the presenting feature in only 15-30% of pediatric cases, which is lower than the adult population (Evans 2009 ). However, incidental findings of VS have been described as early as 4-5 months (Ruggieri et al. 2013) .
Schwannomatosis is described as the presence of multiple schwannomas in the absence of vestibular tumors (Hulsebos et al. 2007 ). Unique histologic features more common to these schwannomas may include Bperitumoral edema, myxoid change and intraneural growth^ . Family history is present in 15-25% of cases (Plotkin et al. 2013) . Germline mutations in SMARCB1 have been identified as one cause but this is not felt to be the only causative gene (Hulsebos et al. 2007 ). SMARCB1 mutations have been identified in 45% of familial and 7% of non-familial cases ). More recently, Piotrowski et al. identified LZTR1 as a second causative gene in schwannomatosis (Piotrowski et al. 2014 ).
Non CNS Solid Tumors
Adrenocortical Carcinoma (ACC) ACC is a rare but aggressive childhood endocrine neoplasm of the adrenal gland that accounts for approximately 0.2% of pediatric cancers (Rodriguez-Galindo et al. 2005) . Typically, ACC occur in young children but can develop at any age. ACC is considered a core tumor in LFS. Approximately 50-80% of all children diagnosed with ACC have LFS (Gonzalez et al. 2009; Ribeiro et al. 2001; Varley 2003; Varley et al. 1999 ) and 7-10% of all LFS patients will be diagnosed with ACC (Gonzalez et al. 2009; Rodriguez-Galindo et al. 2005) . ACC incidence in LFS seems to decrease with age. Individuals with ACC meet National Comprehensive Cancer Network guidelines criteria for germline TP53 regardless of family history, according to revised Chompret criteria ((NCCN) 2017).
Fewer than 1% of individuals with ACC have BeckwithWeidemann syndrome (BWS); however, ACC comprises 15-20% of the tumors that arise in individuals with BWS (Rodriguez-Galindo et al. 2005) . The development of BWSassociated tumors is exclusively restricted to childhood. ACC also occurs in isolated hemihypertrophy/hemihyperplasia, which shares several phenotypic features with BWS (Tan and Amor 2006) . ACC in association with multiple endocrine neoplasia type 1 (MEN1) due to a mutation in the MEN1 gene, FAP, NF1, and Lynch syndrome have been reported but the frequency and average age at diagnosis is not well defined among this subset of ACC patients (Langer et al. 2002; Lerario et al. 2014; Marchesa et al. 1997; Raymond et al. 2013; Smith et al. 2000; Wagner et al. 2005) .
Cardiac Rhabdomyoma (CR)
Primary cardiac tumors are rare and occur at an incidence of 0.2% among infants and children. CRs are benign tumors and the most common pediatric primary cardiac tumor accounting for 60-80% of cases (Bader et al. 2003; Beghetti et al. 1997; Padalino et al. 2014; Yinon et al. 2010) . Approximately 51-86% of individuals with a CR have been reported to have TSC (Harding and Pagon 1990) . CRs may present via ultrasound in utero but infrequently cause hemodynamic problems compromising the pregnancy (Atalay et al. 2010; Bader et al. 2003; Yinon et al. 2010) . CRs usually regress over time and do not require medical or surgical intervention (Bosi et al. 1996; Smythe et al. 1990) . CRs are more common in individuals with mutations in TSC2 than TSC1, are often multifocal, may appear de novo, and can show regrowth during adolescence (Jozwiak et al. 2006) . CRs can also be seen infrequently in individuals with NBCCS (Watson et al. 2004 ).
Desmoid Tumor
Desmoid tumors, also known as desmoid fibromatosis or aggressive fibromatosis, are rare mesenchymal neoplasms, which can occur in various sites including the head, neck, trunk, and intra-abdomen. They arise at a frequency of 2-4 per million per year (Reitamo et al. 1982 ). These tumors behave in a locally aggressive manner and frequently recur. Desmoids are usually sporadic, but can occur as a feature of FAP (Kattentidt Mouravieva et al. 2012; Wang et al. 2012) and may be the first manifestation of the condition. Identifying the presence of a germline APC mutation may help with early detection of polyposis in a child and/or relatives and offer the opportunity to prevent colorectal cancer. Studies support the role of deregulation of the APC/β-catenin pathway in the pathogenesis of desmoid tumors. Molecular testing for somatic mutations of the β -catenin gene, CTNNB1, can be helpful in distinguishing sporadic tumors from those with an inherited cause as desmoid tumors lacking CTNNB1 mutations are more common in FAP patients ).
Endolymphatic Sac Tumor (ELST)
ELSTs are rare, highly vascular, low grade neoplasms that arise from the endolymphatic sac or duct within the temporal bone. Diaz et al. report that ELSTs account for approximately 4% of all tumors/pseudotumors of the endolymphatic sac (Diaz et al. 2007 ). They can occur sporadically but are commonly associated with Von Hippel Lindau syndrome (VHL) (Choo et al. 2004; Hamazaki et al. 2001; Jensen et al. 2004; Manski et al. 1997; Megerian et al. 2002) . The frequency with which ELSTs occur sporadically versus in association with VHL syndrome is not entirely clear, but approximately 11-16% of individuals with VHL develop ELSTs (Choo et al. 2004; Manski et al. 1997) . Of these, 15-30% occur bilaterally (Manski et al. 1997; Megerian et al. 2002) . The average age of diagnosis of ELSTs among those with VHL is 31 years with a range of 11 to 63 years (Megerian et al. 2002) .
Gastrointestinal Tumors

Adenomatous Polyp
Adenomatous polyps consist of benign neoplastic tissue derived from glandular epithelium whose incidence increases with age. A child presenting with adenomatous polyps in the teen years should raise concern for FAP. In its classic form, an individual presents with polyposis in the teen years, developing 100s to 1000s of polyps in one's lifetime. If untreated, the average age for a colorectal cancer (CRC) diagnosis is close to 40 years and it is almost 100% penetrant (Half et al. 2009 ). While polyps begin to develop throughout childhood and/or the teen years, and cancer typically occurs approximately a decade after the onset of polyp development; CRC can occur in childhood (Half et al. 2009) . Because surveillance for polyposis should begin at 10-12 years of age in affected individuals, predictive genetic testing of at risk minors may be authorized by parents or guardians and, ideally, the assent of the child should be obtained (Committe on Bioethics 2013). Therefore, testing is sometimes delayed until a child approaches 10 years of age. Due to the increased risk for hepatoblastoma and other tumors in earlier childhood, however, testing very young children may be considered. In attenuated FAP (AFAP), due to mutations at the 5′ and 3′ ends of the APC gene, polyposis and cancer tend to have adulthood onset and predictive genetic testing decisions may be delayed until adulthood (Buckner et al. 2007 ; Committe on Bioethics 2013). Other considerations include autosomal recessive inheritance of a different gene, MUTYH, which presents with adenomatous polyposis similar to FAP (Buckner et al. 2007 ). This is known as MUTYH associated polyposis (MAP).
Lynch syndrome may or may not be associated with polyps in the pediatric patient (Giardiello et al. 2014) as it is most commonly an adult-onset condition (Durno and Gallinger 2006) . However, polyposis and early onset CRC may develop in individuals with a heterozygous MMR gene mutation. The risk is significantly greater and earlier in those with two MMR gene mutations (ie. CMMRD). The average age of onset among individuals with CMMRD is 16 years (Wimmer and Kratz 2010) .
Lastly, adenomatous polyps/features within polyps may be observed in children with other hereditary syndromes more typically associated with colon adenocarcinomas and/or hamartomatous polyposis (e.g. Peutz-Jeghers syndrome, DICER1 syndrome, etc.) (Beggs et al. 2010; Foulkes et al. 2011 ).
Colorectal Adenocarcinoma
The risk for CRC in individuals <20 years of age is approximately 0.1% of the cases reported among SEER data between 2009 and 2013 (SEER Program National Cancer Institute 2013). Childhood CRC can be associated with CMMRD. One study found that 37/ 92 (40%) individuals with CMMRD had CRC with ages of onset between 8 and 35 years (median age 16 years) (Wimmer and Kratz 2010) . A second study also reported an average age of CRC for individuals with biallelic MLH1 mutations of 17 years (Bruwer et al. 2014) . MSH6 or PMS2 mutations are less penetrant than MLH1 and MSH2 and, therefore, a family history suggestive of Lynch syndrome may not be evident for some individuals with CMMRD (Wimmer and Kratz 2010) . Although typically considered an adult onset condition, Lynch syndrome should also be considered in an adolescent with CRC. A large retrospective study of adolescents and young adults diagnosed with CRC (<35 years) found Lynch syndrome to be the most common diagnosis within their patient population (Mork et al. 2015) .
While CRC is not a core cancer type observed in individuals with LFS, the condition is one of the more frequently associated syndromes with early onset CRC (Sorrell et al. 2013) . The average age of diagnosis of CRC in LFS is approximately 33 years but has been reported to occur in childhood (Wong et al. 2006) . While individuals with CRC due to LFS may have a strong family history suggestive of LFS, family history may be absent due to de novo mutations which occur in 10-25% of individuals with LFS (Sorrell et al. 2013) .
Cases of childhood CRC have been reported in FAP (Half et al. 2009 ) and should be considered in the differential. Other autosomal recessive syndromes, including chromosome breakage syndromes (e.g. Bloom), and chromosomal conditions (e.g. Turner) have also been reported in rare cases of children with CRC ).
Intestinal Hamartoma
The true incidence of intestinal hamartomas among the pediatric population is not clear as most have been described in association with specific syndromes. Polyposis with juvenile histology (also called hyperplastic and/or inflammatory polyps, and lymphoid hyperplasia) can occur in the colon and/or throughout the gastrointestinal tract. The presence of juvenile polyps is suggestive of juvenile polyposis syndrome, JPS (Brosens et al. 2011) . Almost half of individuals with JPS have no family history of the condition (Manfredi 2010) . Individuals with JPS typically develop polyps in the first 2 decades of life, or on average, by 20 years of age (Manfredi 2010) . Individuals with JPS have a 17-68% lifetime risk of developing CRC, and approximately 20% lifetime risk of developing gastric cancer (Jelsig et al. 2014; Manfredi 2010) , although CRC and gastric cancer do not usually present in childhood. Mutations in the SMAD4 (15-20%) or BMPR1A (20-25%) genes account for 35-45% of individuals with JPS. While individuals with BMPR1A mutations usually do not have other physical stigmata, individuals with SMAD4 mutations are also at risk for hereditary hemorrhagic telangiectasia (HHT) and need to be screened accordingly (Manfredi 2010) . Although the clinical sensitivity is low, SMAD4 and BMPR1A genetic testing is significant in differentiating between the two types to determine if HHT screening is necessary.
Peutz-Jeghers syndrome (PJS) can also present with hamartomatous polyps (Manfredi 2010) . The lifetime risk of cancer in individuals with PJS is greater than 90% and (Jelsig et al. 2014 ) half of individuals with PJS present by 20 years of age with small bowel obstruction, intussusception, and/or bleeding due to small bowel polyps. Symptoms present in one third of patients with PJS by 10 years of age (Goldstein and Hoffenberg 2013) . Polyps most commonly occur in the small intestine, but they also occur in the colon and stomach (Manfredi 2010) .
Polyps associated with PHTS are most often hamartomas, but may also include adenomatous, hyperplastic, sessile serrated, ganglioneuromatous, inflammatory, lymphoid, and/or lipomatous polyp types (Jasperson 2012 ). These polyps develop throughout the gastrointestinal tract from the esophagus to the rectum (Jasperson 2012) . The incidence of gastrointestinal polyps in PHTS varies in the literature from 30% to greater than 90% (Manfredi 2010; Tan et al. 2012) . The lifetime risk of CRC has been reported at approximately 7-9% (Jasperson 2012; Tan et al. 2012) , however, the risk to develop CRC in childhood is unclear.
Ganglioneuroma/Mucosal Neuroma
Mucosal neuromas, also known as ganglioneuromas (GNs), are benign neoplasms derived from the autonomic nervous system that may present in the gastrointestinal tract and are primarily associated with NF1, multiple endocrine neoplasia type 2B (MEN2B), and PHTS (Chan and Haghighi 2006; Patil and Chamberlain 2012) . However, GNs have also been reported in association with other hereditary syndromes such as PJS (Vinitsky et al. 2013 ) and mutations in PHOX2B (Bourdeaut et al. 2012) , as described in more detail under neuroendocrine tumors. Approximately 40% of individuals with MEN2B develop intestinal GNs. Only a few GN (not generalized) is usually indicative of NF1 or MEN2B, whereas polyposis may be observed in individuals with PHTS (Vinitsky et al. 2013) . The link between intestinal ganglioneuromatosis and malignancy is not well established, although investigators have described the occurrence of individuals with both ganglioneuromatosis and CRC (Chan and Haghighi 2006) . Reports of ganglioneuromatosis presenting in childhood as an initial manifestation of a hereditary syndrome (PHTS, for example) have been reported infrequently (Vinitsky et al. 2013 ).
Gastrointestinal Stromal Tumor (GIST)
GISTs have an incidence of 0.55-0.78 per 100,000 individuals and 0.5% occur before 20 years of age . They are mesenchymal tumors of the gastrointestinal tract, mostly in the stomach (70%), but also in the small intestine (20-30%), and in the esophagus, colon, appendix or rectum (less than 10%). GISTs historically were referred to as leiomyomas or leiomyosarcomas. Most are benign, but approximately 10-30% are malignant (Sandberg and Bridge 2002) . Sporadic GISTs are rare before the age of 40 years (Miettinen et al. 1999) . Individuals with familial GIST are more likely to have multiple tumors and tend to present 10 years earlier than individuals with sporadic GISTs (Burgoyne et al. 2014) . Most sporadic GISTs are caused by somatic mutations in the KIT or PDGFRA genes and mutations in these genes can cause familial GISTs as well (Burgoyne et al. 2014) . Most (~90%) of GISTs that are KIT/ PDGFRA wild-type, have a germline mutation in SDHA, SDHB, SDHC, or SDHD (Boikos et al. 2016 ). The name Carney-Stratakis syndrome has been used to describe individuals with hereditary paraganglioma syndrome with GISTs.
Other hereditary syndromes that also increase the likelihood of developing GISTs include NF1 and Carney triad (CT) (Burgoyne et al. 2014; Carney and Stratakis 2002) .
Gonadal
Ovarian Sex Cord Stromal Tumor
Ovarian sex cord stromal tumors (SCST) are derived from the sex cords and ovarian stroma or mesenchyma of the embryonic gonads and account for only 1.2% of ovarian cancers (Heo et al. 2014; Quirk and Natarajan 2005) . The tumor should raise concern for DICER1 syndrome, particularly those with Sertoli-Leydig cell tumors (SLCT), which typically arise in childhood to early adulthood (Schultz et al. 2011; Slade et al. 2011) . Studies have reported DICER1 germline mutation rates approaching 60% in those individuals diagnosed with SLCT. Reports in juvenile granulosa cell tumors, gynandroblastoma and unclassified sex chord-stromal tumors have also been described (Stewart et al. 2016) . A second subtype of SCST, sex cord tumors with annular tubules is associated with PJS in approximately 36% of cases (Young et al. 1982) , although these cases are more often reported after adolescence. Cases associated with PJS are more often bilateral multifocal small tumors with focal calcification, whereas sporadic tumors are more commonly unilateral, large and have a greater risk of malignancy (Young 2005) .
Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT)
SCCOHT are aggressive ovarian tumors with genomic and epigenomic features similar to that of ATRTs and more recently have been referred to as malignant rhabdoid tumors of the ovary (Fahiminiya et al. 2016) . They account for 1% of ovarian cancers. The age of onset is broad ranging from as young as 5 to 46 years of age in one report with an average age of onset around 24 years (Ramos et al. 2014b ). Ramos et al. reported SMARCA4 mutations in 19/24 SCCOHT tumors and the absence of SMARCA4 protein staining in 16/19 SCCOHT tumors analyzed. Ramos also described a SMARCB1 homozygous mutation in at least one SCCOHT tumor that retained SMARCA4 protein staining and lacked SMARCA4 mutations, suggesting that SMARCB1 may contribute to a minority of SCCOHT tumors. Additional work has proven that germline and biallelic somatic SMARCA4 mutations in tumors are associated with this unique subgroup of ovarian cancer (Ramos et al. 2014a; Witkowski et al. 2014 ).
Testicular Sertoli Tumor
Testicular sex cord stromal tumors (TSCS) are primary neoplasms of the testis that account for 5% of testicular tumors and include tumors of Leydig, Sertoli, granulosa, and theca cell origins as well as mixed cell types and incompletely differentiated tumors (Dilworth et al. 1991) . Sixty percent of large cell calcifying Sertoli cell tumors (LCCSCTs), a type of TSCS, are sporadic with an average age of diagnosis of 16 years. The remaining 40% of cases are often associated with endocrine disorders including PJS and Carney complex. The cumulative risk of testicular cancer in PJS has been reported to be 9% (van Lier et al. 2010 ) with a mean age of onset of 8.7 years (range 3-20) (Beggs et al. 2010) . About 50% of males with Carney complex will develop LCCSCT (Song et al. 2014) . Most occur post puberty but range in age of diagnosis from 2 to 51 years (Courcoutsakis et al. 2013 ).
Gonadoblastoma
Gonadoblastomas are rare benign gonadal tumors composed of germ cells, sex cord cells, and a cellular stroma, which may give rise to malignant germ-cell tumors (Scully 1970) . Frasier syndrome (FS), caused by mutations in the intron 9 splice site of the WT1 gene, is associated with an increased risk for gonadoblastoma (Barbaux et al. 1997) . Individuals with FS have a 46,XY karyotype but may present with ambiguous or female genitalia, as well as glomerulosclerosis (Haning et al. 1985) . The majority of FS cases are de novo, and most children with FS will not have a family history of the condition.
Turner syndrome is defined by a 45,X karyotype, though many individuals are mosaic. Y chromosome material is identified in up to 6% of patients by karyotype (Mancilla et al. 2003) . Of this subgroup, approximately 15-25% will develop gonadoblastoma (WHO 2004) . In one series of 192 girls with a clinical diagnosis of Turner syndrome, 3/7 mosaic 45,X/ 46,Y cases were diagnosed with gonadoblastoma. Two of these were bilateral (Brant et al. 2006 ).
Hemangioblastoma
Hemangioblastomas are vascular tumors that are commonly found in the CNS (cerebellum, brain stem, and spinal cord) as well as the retina. While usually not malignant, they can cause tremendous morbidity including mobility and visual deficits. Individuals who are symptomatic for a hemangioblastoma have an estimated 10-40% chance of testing positive for VHL (Richard et al. 2000; Sora et al. 2001) . The ages of onset among individuals with CNS hemagioblastomas can range from childhood to adulthood (7-73 years), with an average age of 29.1 years. Individuals with multiple lesions tend to present earlier than those with single lesions (Kanno et al. 2013) . Seventy percent of individuals with VHL develop retinal hemangioblastomas. While they can develop in childhood, the average age of retinal hemangioblastoma onset is 25 years (Kreusel 2005; Webster et al. 1999 ).
Juvenile Nasopharyngeal Angiofibroma (JNA) JNA is a rare tumor of the nasopharynx that is highly vascular and locally invasive and accounts for far less than 1% of all head and neck cancers. The tumor typically affects young males between the ages of 14-25 years (Coutinho-Camillo et al. 2008; Tiwari et al. 2016 ). JNA's are diagnosed 25 times more frequently in patients with FAP than in the general population (Abraham et al. 2001; Ferouz et al. 1995) . Although the pathology of this tumor is not fully understood, it is believed to be related to the APC/[β]-catenin pathway. Ponti et al. showed that lack of APC expression demonstrated by absence of immunohistochemistry staining in tumor can be a marker for germline APC mutations (Ponti et al. 2008 ).
Lipoma
Lipomas are adipose tumors, usually benign, which are the most common soft tissue tumor affecting approximately 1 per 1000 people (Rydholm and Berg 1983) . These tumors are one of the cutaneous features of PHTS and are seen in children (Lachlan et al. 2007 ). In a study of 172 PTEN mutation-positive patients, 47% were reported to have lipomas (Pilarski et al. 2011) . Lipomas are also seen in MEN1 and FAP, although the incidence in childhood is not well described. Both surface and visceral lipomas are seen in more than 33% of individuals with MEN1 and can be numerous (Darling et al. 1997; Vidal et al. 2008) . In a study of 56 individuals with genetically confirmed FAP who underwent dermatologic exams specific to the identification of skin lesions, 55.5% were identified with lipomas, which typically occurred on the extremities (Burger et al. 2011) .
Congenital lipomatous, overgrowth, vascular abnormalities, epidermal nevi, and skeletal anomalies (CLOVES) is caused by mosaic somatic mutations in the PIK3CA gene (Kurek et al. 2012) . Recent studies have suggested that PIK3CA mutations are responsible for a spectrum of conditions including CLOVES, fibroadipose overgrowth (FAO), hemihyperplasia multiple lipomatosis (HHML), isolated macrodactyly, and megalencephaly-capillary malformationpolymicrogyria syndrome. It has been proposed that, together, these syndromes be called PIK3CA-Related Overgrowth Spectrum. Proteus syndrome is a very rare syndrome characterized by asymmetrical, disproportional overgrowth in which lipomas can be seen. It is caused by somatic mosaicism for mutations in AKT1 (Lindhurst et al. 2011) .
Familial multiple lipomatosis has also been described in which multiple, painless, subcutaneous lipomas develop over the torso and limbs. Typically they appear by the third decade but can be seen in childhood. To date no gene has been identified ).
Liver Tumors
Hepatoblastoma
Hepatoblastomas are the most common primary liver tumor in children accounting for a little over 1% of pediatric cancers (Herzog et al. 2000) . The risk for developing hepatoblastoma in children with a family history of FAP has been estimated to be 800 fold greater than the general population (Hirschman et al. 2005) . A study examining the APC germline mutation rate in children with apparently sporadic hepatoblastoma found 10% of cases carried an underlying APC mutation (Aretz et al. 2006 ). Among children with APC mutations, the reported risk for hepatoblastoma ranges from 0.3-1.6% (Aretz et al. 2007; Giardiello et al. 1991) . The average age at diagnosis of hepatoblastoma in individuals with an APC mutation is <3 years and is similar to the average age in the general population, age 4 years (Ries and SEER Program (National Cancer Institute (U.S.)) 1999). Similar to desmoid tumors, studies support the role of deregulation of the APC/β-catenin pathway in the pathogenesis of hepatoblastoma and molecular testing for somatic mutations of CTNNB1, particularly exon 3, can be helpful in distinguishing sporadic tumors from those with an inherited cause (Curia et al. 2008) .
Hepatoblastoma can also be seen in two overgrowth syndromes, BWS and Simpson-Golabi-Behmel syndrome (SGBS). The likelihood of identifying hepatoblastoma is 1000 to 10,000 fold higher in children with BWS (DeBaun and Tucker 1998). In a comprehensive review of >100 tumors reported in BWS, 20% were hepatoblastoma (Lapunzina 2005) . Eighty-five percent of mutations causing BWS arise de novo, while 15% have family history suggesting autosomal dominant inheritance (Li et al. 1997 (Li et al. , 1998 . SGBS is also associated with increased risk for hepatoblastoma (Li et al. 2001) . Currently there are 2 reported cases of hepatoblastoma in individuals with SGBS (Lapunzina 2005) , making hepatoblastoma the second most commonly seen cancer in SGBS.
Hepatocellular Carcinoma
Hepatocellular carcinoma is a rare childhood cancer accounting for 0.5% of all pediatric malignancies . Of the overgrowth syndromes, one case of hepatocellular carcinoma was diagnosed in a 3 year old male with SGBS (Lapunzina et al. 1998) , one case in a child with Sotos syndrome (Lapunzina 2005) , and one case in a child with BWS syndrome (Lapunzina 2005) . In addition, genetic conditions leading to liver disease such as untreated tyrosinemia type I and glycogen storage liver diseases type I and IV, as well as Wilson's disease can predispose to hepatocellular carcinoma (Kelly et al. 2015; Waller et al. 2015) .
Myofibromatosis, Infantile
Infantile myofibromatosis (also known as congenital multiple fibromatosis or juvenile myofibromatosis) is a rare mesenchymal disorder typically arising in infancy which is characterized by solitary or multiple nodules commonly involving the skin, striated muscles and bones, and sometimes, viscera. The skin nodules typically develop under the skin, or in the soft tissue of the head, neck, or trunk of the body (Arcangeli and Calista 2006) . These nodules frequently resolve spontaneously in the first few years after diagnosis, although local morbidity may occur, and late recurrent nodules merit long-term follow up (Mashiah et al. 2014) . Most often, infantile myofibromatosis occurs sporadically; however, recently it has been associated with familial risks due to mutations in the PDGFRB gene. A mutation in a second gene, NOTCH3, has also been reported in a family with infantile myofibromatosis (Martignetti et al. 2013 ). All reports identified by literature search of individuals with myofibromatosis and a PDGFRB or NOTCH3 gene mutation have had family history of the condition.
Neuroendocrine
Neuroblastoma (NB)
NBs arise from cells of the sympathetic nervous system, which have their origins from the neural crest. They most commonly arise in the adrenal gland but can also develop in the neck, chest, and pelvis and account for 5-10% of all pediatric cancers (Linabery and Ross 2008; Park et al. 2008 ). One to 2% of NBs are thought to be hereditary (Mosse et al. 2008 ). In the absence of clear syndromic findings in a child with a positive family history, the primary associated syndrome is familial NB, caused most commonly by mutations in the ALK and PHOXB2 genes (Mosse et al. 2008; Trochet et al. 2004) . NBs due to mutations in these genes are usually bilateral and multifocal. The average age of diagnosis is approximately 9 months compared to 2-3 years in the general population (Park et al. 2008) . ALK demonstrates incomplete penetrance, and penetrance may depend on the familial mutation (Bourdeaut et al. 2012) . Mutations in PHOX2B are less common than ALK (Szymońska et al. 2015) and more recently GALNT14 has also been implicated in hereditary NB (De Mariano et al. 2015) .
The overgrowth syndromes BWS and SGBS carry an elevated risk for NB. Most studies have examined the cumulative risk for embryonal tumors in these syndromes reporting between 4 and 21% in BWS (Elliott et al. 1994; Schneid et al. 1997 ) and around 10% in SGBS (Li et al. 2001) . Childhood cases of NB in Sotos syndrome have also been described (Kulkarni et al. 2013; Nance et al. 1990) NB has been reported in the RASopathies with the highest frequency in Costello and Noonan syndromes. A literature review of more than 1900 cases showed NBs account for approximately 17% of the malignancies seen in Costello and Noonan syndromes with an average age of onset of 0.8 years and 1.4 years, respectively (Kratz et al. 2011) . Associations with LFS (Birch et al. 2001 ) and NF1 (Brems et al. 2009 ) have also be described although the strength of these associations requires further research.
Pancreatic Islet Cell Tumor (ICT)
Islet cell tumors develop in the hormone producing cells of the pancreas and occur in approximately 2.2 per 100,000,000 individuals. Most arise in adults with only~0.1 per 100,000,000 occurring in adolescents, 15-19 years of age (Halfdanarson et al. 2008 ). There are several types of ICT including gastrinomas, insulinomas and glucagonomas. Twenty to 25% of gastrinomas, 7-8% of insulinomas, and 13% of glucagonomas are attributable to MEN1 germline mutations (Roy et al. 2000; Service et al. 1991; Soga and Yakuwa 1998) . Affected individuals have a 40% likelihood of developing gastrinoma, 10% for insulinoma, <5% for glucagonoma, <5% for vasoactive intestinal peptide tumors, and 20% for non-functioning pancreatic polypeptide tumor (Brandi et al. 2001) . Insulinomas tend to occur ten years younger in those with an MEN1 mutation than individuals with a sporadic insulinoma (Marx et al. 1999) , thus screening begins as early as age 5 years (Rich 2008) .
ICTs are also observed in 5-17% (Lonser et al. 2003; Maher et al. 2011 ) of patients with VHL. Amongst cases of ICT in the VHL registry the mean age of diagnosis was 36.8 years with 13 years being the youngest age of diagnosis (Erlic et al. 2010) . These tumors are typically non-secreting but have malignant potential. Rare cases of pancreatic islet cell tumors have been reported in TSC, ranging in age from 6 to 63 years (Arva et al. 2012; Cansu et al. 2014 ).
Non-Rhabdoid Renal Tumors
Cystic nephroma (CN)
CNs are benign, multiloculated, cystic tumors of the kidney and 50% will develop before 4 years of age (Stamatiou et al. 2008) . These lesions are seen in DICER1 syndrome (Slade et al. 2011) . Doros et al. has suggested that a small number of DICER1-associated cystic nephromas have the potential for sarcomatous transformation or progression suggesting that germline DICER1 genetic testing could be considered in early onset renal sarcomas .
Renal Cell Carcinoma (RCC)
Approximately 2% of all sporadic pediatric renal tumors are RCCs (Perlman 2010 (Gudbjartsson et al. 2002) and Shuch et al. state that those with a hereditary predisposition are diagnosed~27 years earlier than their sporadic counterparts (33 vs. 60 years) (Shuch et al. 2014a; Shuch et al. 2014b) . The likelihood for a specific RCC to be hereditary depends on the pathology of the RCC, particularly by histology, aggressiveness, penetrance, and associated clinical manifestations (Shuch et al. 2014a) . Clear cell carcinoma of the kidney is the most common pathology of RCCs associated with VHL and approximately 70% of individuals with VHL develop RCC in their lifetime. RCC is rarely diagnosed before 16 years old, the mean age of diagnosis is 40 years, but asymptomatic tumors are frequently detected earlier (Maher et al. 2011) .
For individuals with bilateral and/or multifocal papillary RCC or a family history of type 1 papillary RCC, hereditary papillary RCC syndrome (HPRCCS) caused by germline MET mutations can be considered. HPRCCS is frequently associated with bilateral and/or multifocal renal tumors (microscopically thousands per kidney). Onset is typically in the fifth, sixth, or seventh decades, but may present earlier, including the second decade of life (Linehan et al. 2009) .
PHTS is also associated with approximately a 35% lifetime risk of RCC (Tan et al. 2012) . The average age of onset in individuals with PHTS is in the 40s, however, cases have been reported in the second decade of life (Tan et al. 2012) . Most RCC in individuals with PHTS show papillary histology, however, other histologies, especially chromophobe type, also occur in individuals with this syndrome .
Pediatric RCC has also been reported more rarely in TSC (Gil et al. 2013; Kubo et al. 2011) and SDHx syndromes .
Wilms Tumor (WT)
WT is the most common type of pediatric renal tumor and accounts for~4% of all childhood cancers (Diniz 2016; Linabery and Ross 2008) The average age of onset is 3-4 years with a range of <1 year of age to the early teens (Faranoush et al. 2009 ). WT may present as a part of a recognized syndrome or as an isolated case. Bilaterality, family history, and other clinical features are all red flags for the hereditary nature of WT (Dumoucel et al. 2014 ). In the absence of a recognized syndrome, hereditary risk for isolated WT may be due to abnormalities in the WT1 gene or 11p15 locus (Segers et al. 2012) . Segers et al. found that 6% of patients with WT and a WT1 mutation had no known clinical syndrome. Four percent of patients with WT and an 11p15 abnormality had only minor, or no, phenotypic features of BWS (Segers et al. 2012) . In this same study, Segers et al. found approximately 5% of individuals with WT had a WT1-related syndrome, including WAGR, Denys-Drash, and FS. WAGR is a contiguous gene syndrome that includes a deletion of both the WT1 and PAX6 genes and confers a 30% risk of developing WT (Dumoucel et al. 2014) . Denys-Drash syndrome is due to point mutations in the zinc finger domain of WT1 (Md Zin et al. 2011) . While the risk for WT is approximately 90% for children with Denys-Drash syndrome (Dumoucel et al. 2014) , patients with FS rarely develop WT (Md Zin et al. 2011) . Both conditions cause normal female external genitalia in individuals with XY karyotypes (Md Zin et al. 2011) . Therefore, the level of concern for WT1 related WT may be greater in phenotypic females than males.
WT has been associated with various overgrowth syndromes. BWS is associated with a 7-30% risk for developing WT depending on the molecular defect. The risk usually approaches population risk by 8 years of age (Dumoucel et al. 2014) . WT also occurs in approximately 6% of individuals with apparently isolated hemihypertrophy (Dumoucel et al. 2014 ). Perlman syndrome is an autosomal recessive overgrowth syndrome caused by biallelic mutations in the DIS3L1 gene. The condition is associated with a 64% incidence of WT in infants surviving beyond the neonatal period and a 55% frequency of bilateral WT (Astuti et al. 2012) . WT is also included in the tumor spectrum seen in children with Sotos syndrome (Lapunzina 2005) .
WT has been reported as an associated cancer risk with LFS (4 of 148 cancers reported in families with LFS instead of the expected 0.034) and may be due to TP53 mutations that impact splicing (Birch et al. 2001) . However, literature is currently lacking regarding the percentage of individuals with WT who have LFS or the percentage of individuals with LFS who develop WT. Other less commonly reported conditions associated with an increased risk for WT include DICER1 syndrome (Bahubeshi et al. 2010; Foulkes et al. 2011; Slade et al. 2011) ,which can have a later age of onset than seen with other hereditary predisposition syndrome, and NF1 (Patil and Chamberlain 2012 ). An increased risk of WT has also been seen in rare long term survivors with Trisomy 18 , as well as rare reported cases of mosaic variegated aneuploidy (MVA) caused by biallelic mutations in BUB1B (Kajii et al. 2001) .
Of children with WT, only 1-2% have a family history of the tumor type. Two chromosomal loci, 17q and 19q, named FWT1 and FWT2, have been implicated in some of these cases (Rapley et al. 2000) . More recently, changes in the gene CTR9 have been implicated in familial WT cases (Hanks et al. 2014) and the gene REST in both familial and non-familial cases (Mahamdallie et al. 2015) .
Autosomal recessive inheritance of genes associated with cancer risk, including BRCA2, PALB2, and BLM, which cause chromosomal breakage syndromes, are also associated with an increased risk for WT (Md Zin et al. 2011; Serra et al. 2012) . Each of these genes is associated with other clinical features and risks when inherited in a recessive manner. While individuals with a heterozygous mutation in these genes also have increased cancer risks, carriers usually do not develop WTs.
Parathyroid Adenoma/Carcinoma
Parathyroid adenomas are benign tumors of the parathyroid gland which can cause primary hyperparathyroidism (PHPT). The incidence of PHPT is estimated to be approximately 2-5 cases per 100,000 cases in the childhood population . Parathyroid carcinoma is a rare cause of PHPT and is associated with 0.5 to 5% of all cases of PHPT (Wynne et al. 1992 ) with only nine reported cases in childhood (Serrano-Gonzalez et al. 2016 ). Thakker reviews the most current understanding of the molecular etiology of parathyroid tumors (Thakker 2016) . Hereditary forms include MEN1, multiple endocrine neoplasia type IV (MEN4), MEN2A, and hyperparathyroidism-jaw tumor (HPT-JT) syndrome (Sharretts and Simonds 2010; Thakker 2016) .
MEN1 is the most common familial cause of PHPT. Parathyroid tumors develop in 95% of affected individuals. Five to 10% of individuals with features suggestive of MEN1 lack a mutation in MEN1. About 3% of these individuals have MEN4 and harbor a mutation in CDNK1B. MEN2A is associated with a~20% chance of parathyroid tumors. Individuals with HPT-JT syndrome develop parathyroid adenomas and carcinoma due to a mutation in CDC73, but they may or may not develop additional associated tumors. In one of the few reported cases of pediatric parathyroid carcinoma in a 14 year old female, a CDC73 germline mutation was identified (Serrano- Gonzalez et al. 2016) . Those with HPT-JT frequently have a single adenoma or carcinoma whereas those with MEN1 usually have multi-glandular parathyroid disease. Cases of isolated familial PHPT have been described yet it is currently unclear whether these cases are due to a distinct genetic etiology or arise as an incomplete manifestation due to a germline mutation in MEN1, CDC73 or CASR. The underlying genetic etiology for many with familial PHPT remains unknown (Sharretts and Simonds 2010; Thakker 2016) .
Pheochromocytoma (PCC) and Paraganglioma (PGL)
PCCs and PGLs are typically benign tumors, which are differentiated based on location. PCCs develop in the adrenal medulla and secrete catecholamines, whereas PGLs develop in extra-adrenal locations along the paravertebral axis and can be either secretory (sympathetic) or non-secretory (parasympathetic). Those located in the head and neck region are referred to as head and neck paragangliomas (HNPGL) and most do not secrete catecholamines (McNicol et al. 2004; Tischler 2004) . PCCs, PGLs, and HNPGLs resulting from germline mutations are often multifocal (although solitary tumors can occur), bilateral, recurrent, and have an early age of onset (Fishbein et al. 2013) . PCC/PGL have an incidence of 2-8 people per million (Beard et al. 1983; Stenstrom and Svardsudd 1986 ) with >20% of these tumors occurring in the pediatric population (Barontini et al. 2006; Ciftci et al. 2001 ) and over 50% are believed to result from a germline mutation (Hammond et al. 2010; Neumann et al. 2002) .
PCCs and PGLs occur in approximately 10-20% of individuals with VHL. While the mean age of development is 30 years, onset can occur prior to 10 years of age (Walther et al. 1999) . PCCs may be the only manifestation of VHL in some individuals and affected persons may lack a family history (Neumann et al. 2002) . Approximately 5% of VHL-related PCCs/PGLs will become malignant (Walther et al. 1999) .
Thirty to 50% of individuals with multiple endocrine neoplasia 2A/2B (MEN2A/2B) develop PCCs, and it is the presenting feature in approximately 25%. The average age at onset is the mid-to-late 30s; however, it has also been reported in the teen years. Two thirds of PCC are bilateral in occurrence and approximately 4% will undergo malignant transformation (Modigliani et al. 1995; Quayle et al. 2007; Rodriguez et al. 2008) .
PCCs occur in individuals with NF1 at a frequency of about 5-15%. Most (84%) are unilateral and do not undergo malignant transformation (Fishbein et al. 2013; Theos et al. 2006 ). While they typically develop in adulthood, there are reports of teenagers with NF1 who have developed a PCC (Bausch et al. 2007 ).
Carney triad (CT) most frequently affects young women and pre-pubescent/pubescent girls (Carney 2013; Matyakhina et al. 2007 ). Affected individuals can develop PGLs in addition to a variety of other tumor types. PGLs are usually benign (Carney 2013) . Seventy eight percent develop at least two unique tumors and 22% will develop three (Carney 1999) . The gene responsible for CT is yet to be identified but analysis of tumors reveal a frequent loss of chromosome 1p and 1q (Matyakhina et al. 2007 ).
PCCs, PGLs, and HNPGLs can be seen in individuals with hereditary pheochromocytoma and paraganglioma syndrome due to mutations in SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, and MAX. Among studies of apparently sporadic PCC, PGLs and HNPGLs, 12-21% of cases have a mutation in SDHB or SDHD, 2% have a mutation in SDHC (Neumann et al. 2004; Peczkowska et al. 2013) , 3% have a mutation in SDHA (Korpershoek et al. 2011) , and 4.2% have a mutation in TMEM127 . Mutations in MAX have been reported in approximately 1% of individuals with familial and non-familial cases (Burnichon et al. 2012) . SDHD, SDHAF2 and MAX display a parent of origin effect (paternally inherited mutation) (Hensen et al. 2004; Lefebvre and Foulkes 2014; Muller 2011) . SDHx tumors display an age-related occurrence (e.g. individuals with mutations in SDHB and SDHD have a 77% and 86% risk, respectively, of tumor development by 50 years of age). Nevertheless, tumors can develop in childhood and the teen years (Benn et al. 2006; Neumann et al. 2004 ). PCCs and PGLs resulting from mutations in SDHB have a high rate of metastasis (van Hulsteijn et al. 2012) .
PGL and somatostatinoma with polycythemia is a rare, recently described hereditary condition that occurs in a mosaic state due to a mutation in HIF2A. There have only been a few reported cases to date with most having had onset in their teens or early adulthood. Affected cases developed multiple PGLs (Pacak et al. 2013) .
The germline mutation detection rate for the above genes among those presenting with PCCs, PGLs, and HNPGLs is reported to be as high as 47% (Fishbein et al. 2013; Peczkowska et al. 2013 ). Mutation identification is higher among those with an early age of onset and/or a family history (Fishbein et al. 2013; Peczkowska et al. 2013 ). Lack of a family history should not exclude the possibility of a heritable condition as 23-34% of patients with identifiable germline mutations have no family history (Fishbein et al. 2013; Jafri and Maher 2012) .
Pleuropulmonary Blastoma (PPB)
PPB is a rare embryonal lung neoplasm. While primary lung neoplasms in children are rare, a variety of histopathologic types occur. The most common type of lung neoplasm in children is carcinoid tumor, but PPBs seem to occur almost as frequently (Yu et al. 2010) . PPB was the first tumor identified to be associated with DICER1 syndrome (Hill et al. 2009 ). It is now felt that nearly 70% of PPBs are associated with germline mutations in the DICER1 gene (Messinger et al. 2015) . Children with a DICER1 mutation are at highest risk of developing a PPB before 6 years of age (Boman et al. 2006) with the majority occurring prior to 4 years of age. There are several types of PPBs classified by differing histologies and average ages of onset: Type Ir (47 months), Type I (8 months), Type II (35 months), and Type III (41 months) (Messinger et al. 2015) .
Retinoblastoma (RB)
RB accounts for~2-3% of childhood cancers with an overall incidence of 1 per 18,000-30,000. It is almost exclusive to children and is the most common malignant eye cancer in childhood (Abramson and Schefler 2004; Linabery and Ross 2008; Society 2003) . RB is a cancer of the light detecting tissue of the eye that most commonly is due to loss of function of both RB1 alleles. RBs typically develop before 5 years of age. While an aggressive cancer in developing countries, it has a cure rate of 95-98% (Abramson and Schefler 2004) . Approximately 40% of all RBs are due to heritable mutations even though 90% of individuals with RB have no family history. This discrepancy is due to reduced penetrance in individuals with RB1 mutations as well as the significant de novo rate of RB1 mutations. Approximately 60-75% of individuals with RB are diagnosed with a unilateral tumor. Of these, 13-15% have a germline RB1 mutation. The remaining 25-40% are diagnosed bilaterally. Almost all individuals with bilateral RB have hereditary RB, though sometimes resulting from somatic mosaicism, thus caution should be used when evaluating a negative blood result in bilateral cases. Tumor RB1 analysis can help to rule out or identify low levels of somatic mosaicism for a mutation. When available, tumor samples can be analyzed as a first step in analysis for individuals with unilateral RB since most RBs have somatic absence of functional RB1 protein. If the abnormalities in both alleles within the tumor are identifiable, then the germline status can be more readily interpreted when testing peripheral blood (Dhar et al. 2011; Richter et al. 2003) . If abnormalities are not detected in the tumor, then blood testing is less informative. Approximately 1% of individuals with RB have MYCN amplification and no RB1 abnormality in the tumor or germline (Felsher 2013) . Should an individual have a chromosomal deletion at 13q including the RB1 gene as well as surrounding genes, they may present with multiple congenital anomalies and/or impairments (Mitter et al. 2011) .
Individuals with an inherited RB1 mutation tend to develop RB at earlier ages (15 months) than individuals with sporadic RBs (24 months) and also have an increased risk to develop second malignancies (Kleinerman et al. 2012; Wong et al. 2014) . Radiation exposure increases the likelihood of developing a second malignancy in patients with RB1 mutations (Marees et al. 2008) . The utility of the incorporation of genetic testing and counseling into the care of retinoblastoma patients and their families has been demonstrated (Dhar et al. 2011) .
Sarcomas
Osteosarcoma
Osteosarcoma is the 8th most frequent tumor resulting in 2-3% of pediatric cancers (Linabery and Ross 2008; Ottaviani and Jaffe 2009) . It is an aggressive malignant neoplasm that has a bimodal age distribution primarily affecting teens between 10 and 14 years and adults after 65 years of age. It commonly occurs in the long bones of the extremities near the metaphyseal growth plates. The 5-year overall survival rate is approximately 65%. It is the most prevalent bone sarcoma in LFS (Calvert et al. 2012) . Osteosarcomas in LFS typically present in the same locations as sporadic osteosarcomas but at younger ages (Ognjanovic et al. 2012) . Some research supports a higher prevalence of LFS in children diagnosed with an osteosarcoma under the age of 10 regardless of family history. (Calvert et al. 2012; Villani et al. 2011) Osteosarcomas are the second most common malignancy found in individuals with hereditary RB. Historically, secondary osteosarcomas have been found within the treatment field of radiation for the primary RB; however, individuals with hereditary RB have been shown to have an increased risk of osteosarcoma over the general population irrespective of radiation exposure for RB treatment (MacCarthy et al. 2009 ). When they arise, the majority do so in the teen years (Chauveinc et al. 2001) .
Three rare, autosomal recessive syndromes also have an increased risk of developing osteosarcomas; RothmundThomson syndrome (RTS), Diamond-Blackfan anemia (DBA), and Bloom syndrome (BS). The prevalence of osteosarcoma in RTS has been reported between 31 and 62% with a mean age of diagnosis between 11.5-14 years. Multicentric osteosarcomas are found in 6.8% of reported cases (Stinco et al. 2008; Wang et al. 2001) . One study found that 31.5% of all osteosarcomas in individuals with RTS occurred before 10 years of age (Stinco et al. 2008) . Wang et al. found that individuals with RTS who have truncating mutations in RECQL4, are at increased risk of developing osteosarcomas (Wang et al. 2003) . This data suggests the genotype/ phenotype relationship might be useful in determining who is most appropriate for osteosarcoma surveillance. Individuals who have a clinical diagnosis of RTS but no identifiable mutations are thought to not be at increased risk of developing osteosarcomas (Larizza et al. 2010) . The prevalence of osteosarcomas in DBA and BS is low (0.86% and 2% respectively) (German 1997; Lee et al. 2004) but still occur at a higher frequency than seen in the general population. Among the few with DBA and osteosarcoma, the age of occurrence has ranged from early childhood to young adulthood (4-22 years) (Lipton et al. 2001) .
Rhabdomyosarcoma (RMS)
RMSs are highly malignant, aggressive tumors that arise from striated undifferentiated muscle cells. There are different types including embryonal (botryoid and spindle cell), alveolar, and anaplastic (Newton et al. 1995; Qualman et al. 1998) . These tumors primarily affect children and teens with the majority occurring before 10 years of age (Arndt and Crist 1999) . RMSs are said to be the most common soft tissue sarcoma amongst this age group, accounting for 2-3% of all childhood cancers, with an overall incidence of 4.5 cases per 1 million children (Linabery and Ross 2008; Ognjanovic et al. 2009) .
LFS is the most significant heritable contributor to the development of RMS (Ognjanovic et al. 2012 ). Ognjanovic's 2012 study reports a mean age of RMS diagnosis that is 3.7 years younger than in the general population (4.3 years vs. 8 years). RMSs in LFS almost exclusively occur in children under the age of 5 years, particularly children less than 3 years (Diller et al. 1995) . Individuals with rhabdomyosarcoma of embryonal anaplastic subtype meet National Comprehensive Cancer Network genetic testing criteria for germline TP53 testing regardless of age and family history, according to revised Chompret criteria ((NCCN) 2017).
While not extremely common, RMSs occur at rates greater than expected in the following syndromes: BWS, Costello syndrome, Noonan syndrome, NF1, CMMRD, and DICER1 syndrome. There have been 7 reported cases of RMSs in children with BWS. Interestingly, 6 of these 7 RMSs have been alveolar (Smith et al. 2001 ). There have been 10 reported cases of RMSs in individuals with Costello syndrome (Gripp et al. 2002) and 9 cases of RMSs in individuals with NF1 (Bien et al. 2007; Cecen et al. 2011) , showing a small but increased incidence of RMS in these genetic syndromes. Cases, specifically of the embryonal subtype, have also been reported in Noonan syndrome (Denayer et al. 2010; Jongmans et al. 2010) . While the literature is limited on RMS in individuals with CMMRD, there is growing evidence that this cancer should be included as a part of the CMMRD spectrum (Kratz et al. 2009 ). Individuals with DICER1 syndrome are at an increased risk of developing embryonal RMS (ERMS) of the cervix, bladder, uterus and abdomen (Doros et al. 2012) . Females with DICER1 syndrome appear to be at increased risk of developing a rare form of RMS, uterine cervix embryonal RMS (cERMS), predominantly botryoid type, mostly in their pre-teen and teen years Foulkes et al. 2011; Tomiak et al. 2014) . Rare cases of RMS, specifically botryoid and embryonal, have also been described in MVA.
Skin
Basal Cell Carcinoma (BCC)
BCC affects over 700,000 individuals annually and when present in the pediatric population, it is usually caused by a genetic condition (LeSueur et al. 2000) . It is the most common non-melanoma skin cancer (Diepgen and Mahler 2002) and, when seen in childhood, it is often associated with NBCCS. BCCs first appear in individuals with NBCCS around puberty but have been reported as early as age 1 year (Shanley et al. 1994) with an average age of 20 years (Kimonis et al. 1997) . Approximately 20-30% of NBCCS cases are thought to be de novo but for many a family history is present (Nikolaou et al. 2012) . After the discovery of PTCH1, a second gene now termed PTCH2, has also been reported in families with NBCCS (Smyth et al. 1999) .
BCCs are estimated to be present in 2% of individuals with RTS (Wang et al. 2001) . They can also be seen in xeroderma pigmentosum (XP) (median age of 8-9 years), Bazex-DupreChristol syndrome (as early as 3-5 years but typically with an onset after the first decade), and albinism (Abuzahra et al. 2012; Kuvat et al. 2011; Nikolaou et al. 2012) .
Melanoma
Melanoma originates from the melanocytes in the basal layer of the epidermis and is the most dangerous form of skin cancer. Melanoma accounts for only approximately 1% of all malignancies in children under 15 years of age, but 7% of malignancies between 15 and 19 years of age. In addition to genetic risk factors, other factors such as giant congenital melanocytic nevi, immunosuppression, or treatment for another childhood cancer also pose a risk for melanoma (Tricoli et al. 2016) . CDKN2A mutations are associated with hereditary melanoma and pancreatic cancer syndrome, also described as familial atypical mole-malignant melanoma syndrome (Zuo et al. 1996) . Studies have shown that approximately 1.5% of individuals with early onset melanoma have mutations in this gene (Pappo 2003) . Helgadottir et al. described an average age of 40 years at the time of first melanoma diagnosis among 104 CDKN2A mutation positive individuals. However, the age at first melanoma diagnosis ranged from 16 to 86 years (Helgadottir et al. 2016) .
Several conditions can predispose young adults transitioning to adulthood with melanoma. Mutations in CDK4 are associated with susceptibility to cutaneous malignant melanoma (Nikolaou et al. 2012 ). Puntervoll et al. describe an average age at first melanoma diagnosis of 39 years with an age range of 18-86 years among 95 mutation positive persons (Puntervoll et al. 2013) . Approximately 5% of individuals with XP will develop melanoma with a median age of diagnosis of 19 years (Pappo 2003) . Other genes have been associated with familial melanoma such as BAP1, POT1, ACD, TERF2IP, and TERT but less is known about these genes and their association with pediatric-onset melanoma (Read et al. 2016) .
Squamous Cell Carcinoma (SCC)
SCC develops in the squamous cells found in the epidermis of the skin but they are also found in the lining of the digestive tract, mouth, lungs, esophagus, bladder, prostate, lung, vagina and cervix. There are over 700,000 cases of SCC diagnosed annually in the US (Rogers et al. 2010) .SCC can be seen in children with XP with a median age of first neoplasm (along with BCCs) of 8 years old (Kraemer et al. 1987) . SCC is the most common skin tumor in oculocutaneous albinism, and although most reports have been in adults, childhood cases have been reported (Alexander and Henschke 1981; Luande et al. 1985) . Individuals with FA are also at risk for SCC (Nikolaou et al. 2012 ). The risk is especially high for head and neck SCC. In the International Fanconi Anemia Registry, 3% of individuals were diagnosed with head and neck SCC with an age range of 15-49 years (Kutler et al. 2003a) . Individuals with dyskeratosis congenita (DC) are at increased risk for SCCs of the rectum, vagina, and cervix. Most cases have been reported in adulthood although cases in older children have been reported (ages 14 and 17 years) (Alter et al. 2013; Anil et al. 1994 ). An increased risk for SCC is associated with RTS and BS, although the incidence is childhood is not well described (German 1997; Wang et al. 2001 ).
Thyroid cancer
Medullary Thyroid Cancer (MTC)
Less than 5% of thyroid cancer arises from the parafollicular, or medullary, cells. Twenty-five to 30% of these MTCs are thought to be hereditary, due to mutations in the RET gene and (Bergholm et al. 1990; Romei et al. 2015) are typically diagnosed at a younger age than sporadic medullary thyroid cancer (36 vs 50 years old) (Pelizzo et al. 2007) . RET mutations cause MEN2; however, depending on the specific mutation, a patient may present with MEN2A (23.7% of RET mutations), MEN2B (8.7% of RET mutations), or Familial Medullary Thyroid Cancer (FMTC) (67.7% of RET mutations) (Romei et al. 2015) . In patients with a RET mutation, the thyroid cancer is more likely to be multifocal and bilateral and is more often associated with C-cell hyperplasia (Wolfe et al. 1973 ). Given known genotype-phenotype correlations, germline testing can be informative in determining future cancer risks and appropriate surveillance (American Thyroid Association Guidelines Task et al. 2009; Chen et al. 2010; Romei et al. 2015) . For example, MEN2B is associated with the youngest onset of thyroid cancer, with a 100% risk of thyroid cancer presenting in very early childhood, as early as infancy (Skinner et al. 1996) . Intervention with thyroidectomy before age 1 year is recommended in infants with MEN2B; because of this, germline genetic testing in infancy is very appropriate. In contrast, while 95% of individuals with MEN2A will also develop MTC, cancer is more often diagnosed in early adulthood, before age 35 , though a diagnosis in the late teens has been observed and thyroidectomy is often recommended in early childhood. Individuals with FMTC typically only develop MTC. The age at diagnosis tends to be later than for individuals with MEN2B or MEN2A, after the fourth decade of life (Krampitz and Norton 2014) .
Non-Medullary Thyroid Cancer
Thyroid cancers of non-medullary origin are classified into four groups: papillary, follicular, Hürthle cell, and anaplastic. Approximately 5% of these non-medullary thyroid cancers are thought to be familial (Alsanea and Clark 2001; Nose 2008 ). Carney complex is associated with increased risk for multiple thyroid adenomas and thyroid cancer, both papillary and follicular type, and the onset is in childhood (Stratakis et al. 1997) . Individuals with DICER1 syndrome have an increased risk for thyroid cancer, with the age range in ten reported cases between 6 and 17 years (de Kock et al. 2014b; Ramasubramanian et al. 2013; Schultz et al. 2014) . Nonmedullary thyroid cancers may also be caused by a RET mutation. One study ) demonstrated that 9.1% of patients carrying a mutation in the RET gene, specifically in codons 790, 791, and 804, had a diagnosis of papillary thyroid carcinoma. However, this association needs to be studied further.
Thyroid cancer has been observed in pediatric patients with germline PTEN mutations. In one prospective series (Ngeow et al. 2011) , six pediatric cases of thyroid cancer were diagnosed, including four children with papillary thyroid cancer, one follicular thyroid cancer, and one Hürthle cell carcinoma. As a result, Bubien et al. have recommended thyroid surveillance in children with PTEN mutations, though not all guidelines have adopted this stance (Bubien et al. 2013) . Thyroid cancer can also be seen in 1-2% of those with FAP. While most arise in between 25 and 28 years of age, cases in childhood and the late teens have been reported. Those with a mutation in codons 140-1309 (especially those with mutations proximal to codon 528, codons 1061 and 1309) have a greater risk of papillary thyroid cancer (Septer et al. 2013; Soravia et al. 1999 ).
Hematological Cancers (aka liquid tumors) Leukemia
Leukemia is a cancer of the blood forming tissue and is classified by the cells affected. For example, myeloid leukemia affects the myeloblasts, while lymphocytic leukemia affects the lymphocytes (NCI 2017) . It is the most common childhood malignancy accounting for about 30% of pediatric cancers (Linabery and Ross 2008) . In recent years several genes with a role in predisposition to myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have come to attention. One of the first described is familial platelet disorder with predisposition to AML (FPD/AML) caused by germline mutations in RUNX1. Individuals carrying a RUNX1 mutation have a lifelong risk of developing hematologic malignancies, specifically AML (Song et al. 1999) . Although only a few families have been reported with RUNX1 germline mutations to date, the incidence of AML seems to be between 20 and 60% (Seif 2011) with a median age of diagnosis around 33 years (range 6-76 years) (West et al. 2014) . It has been suggested that children with undifferentiated AML should be evaluated for RUNX1 mutations (Seif 2011) . The CEBPA gene has also been linked to familial AML (Smith et al. 2004) with the age at presentation ranging from 4 years to older than 50 years (Pabst et al. 2008; Renneville et al. 2009 ). Families carrying CEBPA mutations typically do not have additional phenotypic features and display nearly complete penetrance for AML (Nickels et al. 2013) . Mutations in GATA2 have been seen in MDS/AML families (Gao et al. 2014; Hahn et al. 2011) , which has overlapping clinical features of immune deficiency in MonoMAC syndrome Dickinson et al. 2011 ) and lymphedema in Emberger syndrome (Ostergaard et al. 2011) , along with the propensity to AML or MDS. Childhood cases of leukemia have been reported among those with GATA2 mutations (Hahn et al. 2011) .
Familial mosaic monosomy 7 typically presents with early onset bone marrow failure or insufficiency and can progress to MDS and AML. The disease is most often fatal. Although monosomy 7 is a common somatic finding in AML, several familial cases have been reported with an age at diagnosis ranging from 3 to 42 (mean~12 years). The causative gene is not known (Carroll et al. 1985; Chitambar et al. 1983; Kwong et al. 2000; Porta et al. 2007; Stieglitz and Loh 2013) The genes ETV6 and ANKRD26 have been associated with dominant transmission of thrombocytopenia with a predisposition to acute leukemias (Kirkpatrick et al. 2015; Zhang et al. 2015b) . A study of over 4000 pediatric ALL cases identified ETV6 variants in 1% of cases. Children with a hyperdiploid leukemia type were overrepresented within the population and tended to have a later age of onset, 10.2 years versus 4.7 years (Moriyama et al. 2015) . ANKRD26 has been also been described in association with thrombocytopenia and the predisposition to myeloid malignancies such as AML, MDS, and CML. Among 224 mutation carriers in two studies, 4.9% had acute leukemias, 2.2% MDS, and 1.3% CML. While some are described as having developed thrombocytopenia in childhood, most who developed malignancy did so in adulthood (Noris et al. 2013) . The true role ETV6 and ANKRD26 play in childhood versus adult leukemia has yet to unfold. Mutations in PAX5 have been implicated in familial cases of pre-B cell ALL with autosomal dominant inheritance and incomplete penetrance. Reported mutation positive cases with ALL are from three families ranging in age from one month to 8 years (Auer et al. 2014; Shah et al. 2013) .
The association between Down syndrome (DS) and leukemia has been recognized since the 1950s (Krivit and Good 1957) . The prevalence of DS among children with ALL is approximately 2% while among children with AML it has been reported between 2 and 14% (Cheng et al. 2009; James et al. 2008; Zeller et al. 2005) . Most ALL cases are B-cell precursor ALL with hyperdiploidy. The average age of leukemia onset is usually before 6 years with the average age of 4 years at the time of diagnosis of ALL. Most cases of AML develop around 1-2 years of age (James et al. 2008; Zeller et al. 2005) .
A second ALL subtype, with intrachromosomal amplification of one copy of chromosome 21, iAMP21, has been associated with constitutional Robertsonian translocation between chromosomes 15 and 21, rob(15;21)(q10;q10)c. Research suggests that the translocation has a structural abnormality that predisposes to chromothripsis after replication leaving carriers with a significantly increased risk, approximately 2700 fold, for developing iAMP21 ALL (Li et al. 2014) .
Childhood leukemia has been described in association with LFS (Powell et al. 2013) . Hypodiploid ALL is characterized by aneuploidy and poor prognosis. Recent studies have shown that individuals with low-hypodiploid ALL have a high likelihood of having LFS (Holmfeldt et al. 2013 ). The age of onset for this subtype among those with LFS has yet to be established.
Several DNA damage repair conditions have an associated risk of leukemia. This increased risk has been well described in CMMRD, most commonly ALL. The average age of onset is 6 years (range 2-21 years) (Wimmer et al. 2014) . Ataxia telangiectasia (AT) is caused by biallelic inactivation of the ATM gene. In one cohort of patients with AT, nearly 20% developed hematologic malignancies with a mean age at diagnosis of 11.4 years (Micol et al. 2011) , with ALL being the most common type of leukemia. In a study documenting malignancies among those with BS (n = 168), 21(12.5%) were diagnosed with leukemia. ALL had the youngest mean age of onset of 13 years (German 1997) .
NBS is characterized by genomic instability and a predisposition to cancer. ALL and AML have been described as secondary malignancies among individuals with NBS, primarily those with a primary of B-cell lineage (Pastorczak et al. 2016) . Heterozygous mutation carriers have also been identified as having a risk for leukemia. Most studies to date have been among individuals from German, Polish, Russian and Slavic origins. The 643C > T, 657del5, and 511A > G variants have been seen among some pediatric patients with ALL. While the risk of ALL is elevated among mutation carriers, it does not appear to be a major risk factor for pediatric leukemia (Chrzanowska et al. 2006; di Masi and Antoccia 2008; Varon et al. 2001 ).
An increased risk for leukemia is also seen in bone marrow failure disorders. In the International Fanconi Anemia Registry, 199 malignancies were reported in 754 individuals with FA, and 60% of these were hematologic malignancies with most (84%) being AML (Kutler et al. 2003b) . Although 90% of individuals with FA will present with bone marrow failure (peak age 6-7 years), approximately 1% will first present with AML (Velez-Ruelas et al. 2006) . Those with FANCD1 have a 50% risk of leukemia by 7 years of age compared to a 20% risk by age 40 years among those with mutations in other FA genes (Alter 2014) . These patients also tend to have intolerance to standard doses of alkylating agents so it is an important diagnosis to recognize for treatment purposes (Mehta et al. 2007) . DBA is a disease of isolated red blood cell production failure and usually presents in the first year of life (Ball 2011) . Fifty percent of patients will have characteristic facial features and may have other differences on clinical exam (Chirnomas and Kupfer 2013) . Individuals with DBA have a 25% lifetime risk of AML (Janov et al. 1996) . Individuals with DC have cumulative incidence of AML of 10% by the age of 50 years (Alter et al. 2010) . Individuals with Shwachman-Diamond syndrome (SDS) have a 5% risk of leukemia including AML, as well as ALL and CML (Chirnomas and Kupfer 2013) . Because of the rarity of these conditions, the incidence in childhood specifically has not been well reported. Cases of leukemia have also been reported in congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii syndrome (Alter 2007; Ballmaier and Germeshausen 2011) , Sotos syndrome and MVA (Hanks et al. 2004; MartinezGlez and Lapunzina 2007) .
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myelodysplastic disorder. Approximately 10-15% of JMML occurs in children with NF1 and typically develops in infancy to early childhood (Niemeyer et al. 1997; Steinemann et al. 2010) . Patients with Noonan syndrome or Noonan spectrum of disorders due to germline mutations in PTPN11, KRAS2, and CBL also have shown an increased risk for the disorder in infancy to early childhood (Choong et al. 1999; Lachenaud et al. 2014; Niemeyer et al. 2010; Strullu et al. 2014) .
Lymphoma
Lymphomas are neoplastic disorders of lymph system and are classified by cell type and degree of differentiation (NCI 2017) . The DNA damage repair defects including AT, BS, and NBS can all contribute to lymphoma predisposition (Gao et al. 2014; Taylor et al. 1996) . Individuals with AT have an increased risk for B-cell lymphomas or Hodgkins disease (Murphy et al. 1999) . Individuals with NBS have an increased risk of bone marrow failure and lymphoid malignancies, the majority of which are B-cell lymphoma predominately in childhood (2000) . Those who are heterozygous NBS mutation carriers are also at increased risk for lymphoma, more often non-Hodgkins lymphoma (NHL) vs. Hodgkins lymphoma (HL) (Chrzanowska et al. 2006; di Masi and Antoccia 2008) . Of the cancer diagnoses seen in BS, 15% are lymphomas (Gao et al. 2014) . The median age of diagnosis is 20 years but cancer in children has been reported (German 1997) . Non-Hodgkin's lymphoma is the most common hematologic malignancy in CMMRD, for which the average age of onset is 5 years (range 0.4-17 years) (Wimmer et al. 2014) . Cases of lymphoma have also been reported in LFS (Gonzalez et al. 2009 ) and Sotos syndrome (Martinez-Glez and Lapunzina 2007) . Lymphomas have also been well described in immunodeficiency syndromes although lymphoma is rarely the cardinal sign in these conditions (Tran et al. 2008) .
Conclusion
Given increased understanding of the associations between various tumor types and specific cancer predisposition syndromes, and increased use of genetic testing technologies, the landscape of pediatric cancer genetics/genomics will only continue to evolve. Providers can now choose from a menu of genetic testing options including single gene testing, cancer specific panels, personalized gene panels, exome/genome sequencing, and somatic tumor testing. These technologies are also rapidly increasing general knowledge of the expanding phenotypes associated with cancer predisposition syndromes in childhood, as well as helping to identify additional genes, which predispose children to cancer. It is becoming increasingly important for oncologists, pathologists, geneticists, genetic counselors, and other providers caring for children with cancer to work together.
This review serves as a starting place in the recognition of those patients at greatest risk for genetic susceptibility to cancer. Important future directions within the field include the multidisciplinary development of pediatric cancer genetic referral guidelines, genetic testing algorithms, resource repositories, and/or surveillance protocols specific to caring for children with, or at-risk for having, a cancer predisposition syndrome. With combined expertise, individuals (cancer patients and at-risk relatives) who are at an increased risk for additional cancers and who may benefit from altered medical management and/or screening can be identified and managed appropriately.
Currently, identification of cancer predisposition syndromes in children rarely plays a role in immediate cancer treatment. However, as genomic technologies and the field of personalized medicine continue to grow, this may change over time. A direct impact of genetic counseling and/or testing in the pediatric cancer setting may also be psychosocial. A significant outcome of identifying these patients and families is answering the important questions families may ask including, BWhy did this happen?^and BCan this happen again?Â dditionally, providing patients and their at-risk relatives with guidance in the prevention of other cancers in the future, through recommended testing, surveillance or awareness can greatly impact care. Cancer genetics should be included as part of the multidisciplinary care of children with cancer who are at risk for having cancer predisposition syndromes and will become increasingly important as the field moves forward.
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